The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin: In vitro Bewertung von Voriconazol gegenüber klinischen Isolaten von Hefen, Schimmelpilzen und Dermatophyten im Vergleich mit Itraconazol, Ketoconazol, Amphotericin B und Griseofulvin
Abstract
Summary. The in vitro activity of voriconazole (UK‐109, 496), a new antifungal triazole derivative, against 650 clinical isolates of yeasts, moulds and dermatophytes was compared with that of itraconazole, ketoconazole, amphotericin B and griseofulvin. The geometric means of the minimum inhibitory concentrations (MICs) of voriconazole were 0.05 μg ml‐1 against yeasts (n= 187), 0.58 μg ml‐1 against moulds (n= 260) and 0.08 μg ml‐1 against dermatophytes (n= 203). The overall activity of voriconazole against yeasts and moulds was good, being similar to that of itraconazole, ketoconazole and amphotericin B. Voriconazole was highly effective against Aspergillus fumigatus (mean MIC 0.23 μg ml‐1) and other Aspergillus species and showed noteworthy activity (mean MICs 0.08‐0.78 μg ml‐1) against emerging and less common clinical isolates of opportunistic moulds, such as Altenaria spp., Cladosporium spp., Acremonium spp., Chrysosporium spp. and Fusarium spp. On the other hand, voriconazole was less active in vitro than the comparative agents studied against various species of zygomycetes, such as Mucor spp., Rhizopus spp. and Absidia spp. Voriconazole and the other two azoles, itraconazole and ketoconazole, were more active than griseofulvin in vitro against most dermatophytes tested. Zusammenfassung. Die In‐vitro‐Aktivität von Voriconazol (UK‐109,496), einem neuen antimy‐kotischen Triazol‐Derivat, wurde gegen 650 klinische Isolate von Hefen, Schimmelpilzen und Dermatophyten mit Itraconazol, Ketoconazol, Amphotericin B und Griseofulvin verglichen. Die mittieren MHK‐Werte (minimalen Hemmkonzentrationen) betrugen gegenüber Hefen 0.05 μg ml‐1 (n= 187), Schimmelpilzen 0.58 μg ml‐1 (n= 260) und Dermatophyten 0.08 μg ml‐1 (n= 203). Insgesamt war die Aktivität von Voriconazol gegen Hefen und Schimmelpilze gut und vergleichbar mit Itraconazol, Ketoconazol und Amphotericin B. Voriconazol war sehr wirksam gegen Aspergillus fumigatus (mittlere MHK 0.23 μg ml‐1) und andere Aspergillus‐Spezies und zeigte ein bemerkenswerte Aktivität (mittlere MHK 0.08‐0.78 μg ml‐1) gegen aufkommende und bisher weniger häufige klinische Isolate opportunistischer Schimmelpilze wie Alternaria spp., Cladosporium spp., Acremonium spp., Chrysosporium spp. und Fusarium spp., Andererseits war Voriconazol in vitro gegen verschiedene Spezies von Zygomyceten wie Mucor spp., Rhizopus spp. und Absidia spp. weniger wirksam als die untersuchten Vergleichssubstanzen. Voriconazol und die anderen beiden Azole, Itraconazol und Ketoconazol, waren in vitro gegen die meisten geprüften Dermatophyten wirksamer als Griseofulvin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the administration of azoles for treating fungal infections has encountered certain limitations, such as their low water solubility, low bioavailability, and frequent side effects consequent on the requirement of high doses and/or long-term administration.21,42”
Citations
Cites
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Therapeutic Outcome in Invasive Aspergillosis
Denning, D. W. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.3.608 · Cited by 683
Oral Azole Drugs as Systemic Antifungal Therapy
Wood, A. J. J., Como, J. A., & Dismukes, W. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300407 · Cited by 596
Fungal infections in cancer patients: An international autopsy survey
Bodey, G. P., Bueltmann, B., Duguid, W. P., Gibbs, D. L., Hanak, H., Hotchi, M., Mall, G., Martino, P., Meunier, F., Milliken, S., et al. (1992) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01967060 · Cited by 546
NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis
Denning, D. W., Lee, J. Y., Hostetler, J. S., Pappas, P. G., Kauffman, C. A., Dewsnup, D. H., Galgiani, J. N., Graybill, J. R., Sugar, A. M., Catanzaro, A., et al. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90023-x · Cited by 448
Powderly, W. G., Saag, M. S., Cloud, G. A., Robinson, P. A., Meyer, R. D., Jacobson, J. M., Graybill, J. R., Sugar, A. M., McAuliffe, V. J., Follansbee, S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203193261203 · Cited by 351
Non-Candida fungal infections after bone marrow transplantation: Risk factors and outcome
Morrison, V. A., Haake, R. J., & Weisdorf, D. J. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90088-4 · Cited by 214
Radford, S. A., Johnson, E. M., & Warnock, D. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.841 · Cited by 188
In vitro evaluation of voriconazole against some clinically important fungi
McGinnis, M. R., Pasarell, L., Sutton, D. A., Fothergill, A. W., Cooper, C. R., & Rinaldi, M. G. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1832 · Cited by 132
Antifungal Agents in the 1990s
Kauffman, C. A., & Carver, P. L. (1997) · Drugs · doi:10.2165/00003495-199753040-00001 · Cited by 129
Cited by
Sorted by citations
Items 101–140 of 140
Gerlinger, I., Fittler, A., Mayer, A., Patzkó, Á., Fónay, F., Pytel, J., & Botz, L. (2008) · Orvosi Hetilap · doi:10.1556/oh.2008.28410 · Cited by 8
Smith, K., Maxwell, L. K., Gull, T. B., Payton, M. E., & Gilmour, M. A. (2014) · Veterinary Ophthalmology · doi:10.1111/vop.12155 · Cited by 8
Topical 5% Natamycin With Oral Ketoconazole in Filamentous Fungal Keratitis
Rajaraman, R. (2015) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000161 · Cited by 8
In vitro antifungal susceptibility of nondermatophytic keratinophilic fungi.
Guarro, J., Pujol, I., Aguilar, C., Ortoneda, M., & Kushwaha, R. K. S. (2000) · Cited by 7
Cutaneous Infections by Geotrichum spp.
Román-Montes, C. M., Sifuentes‐Osornio, J., & Martínez‐Gamboa, A. (2024) · Current Fungal Infection Reports · doi:10.1007/s12281-024-00481-9 · Cited by 5
Mucormycosis in pediatric oncology patients: a hospital outbreak investigation report
Saleem, A. I. H., Alsaedi, A., Alharbi, M., Abdullah, S., Rabou, A. A., & Al-Dabbagh, M. A. (2021) · Infection Prevention in Practice · doi:10.1016/j.infpip.2021.100189 · Cited by 5
Verticillium infection—a rare cause of hepatosplenic abscesses
Wu, C.-J., Chang, T. C., Lee, H., Chen, T., Lee, N., Chang, C., Chen, P., Shih, M. J., Peng, S.-L., & Ko, W. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.07.012 · Cited by 5
A REVIEW OF OCULAR FUNGAL INFECTIONS OTHER THAN KERATOMYCOSIS: THE GLOBAL AND INDIAN SCENARIO
Sarkar, S., Bhattacharya, T. K., Roy, A., & Ghosh, K. (2016) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2016/734 · Cited by 5
Antifungal activity of eukaryotic microalgae in dermatophytes
Lage, V. M. G. B., Deegan, K. R., Santos, G. F., Fernandez, L. G., Barbosa, C. D. J., & Lima, S. T. D. C. (2023) · Revista de Ciências Médicas e Biológicas · doi:10.9771/cmbio.v22i4.52706 · Cited by 5
Some new azole type heterocyclic compounds as antifungal agents
July, R., December, R., & December, A. (2014) · Cited by 4
Isolation of fluconazole-tolerant micromycetes onto different cultivation media
Kunová, Z. Z., & Piecková, E. (2002) · Folia Microbiologica · doi:10.1007/bf02817667 · Cited by 4
Gedik, O. Y. H. (2015) · Journal of Blood Disorders & Transfusion · doi:10.4172/2155-9864.1000s5-001 · Cited by 3
Fungal infections—Background to specific fungal species
Sokóvić, M., & Λιάρας, Κ. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815824-1.00002-0 · Cited by 2
Yousefi, J., Akhavan, A., Hoseini-Motlagh, R., Banaei-Boroujeni, S., Panahi, Y., & Khosravi, M. H. (2017) · Razavi International Journal of Medicine · doi:10.5812/rijm.64550 · Cited by 3
Pharmacological agents in development for invasive aspergillosis
Meis, J. F. G. M., & Ruijgrok, E. J. (2002) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.7.1.33 · Cited by 3
Bow, E. J., & Bacteriol, D. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0005-y · Cited by 2
Seebacher, C. (2004) · Der Hautarzt · doi:10.1007/s00105-003-0661-8 · Cited by 2
Resistance to Antifungal Agents
Arıkan, S., & Rex, J. H. (2010) · Wiley eBooks · doi:10.1002/9780470688618.taw0136 · Cited by 2
Antifungal Treatment (Topical/Systemic)
Hsieh, J. W., & Landis, B. N. (2024) · Springer eBooks · doi:10.1007/978-3-031-33199-2_27 · Cited by 1
Mucormykose durch Mycocladus corymbiferus bei einem Mastschwein
Zeeh, F., Zimmermann, W., Eichhorn, L., Welle, M. M., Blaser, P., & Albini, S. (2010) · Schweizer Archiv für Tierheilkunde · doi:10.1024/0036-7281/a000118 · Cited by 1
ESCMID/ECMM Joint Clinical Guideline for the Diagnosis and Management of Rare Invasive Yeast
Arendrup, M. C., Boekhout, T., Akova, M., & Cornely, O. A. (2013) · Cited by 1
García, Y. S., Humbría-García, L., & Valles, R. C. H. (2015) · PubMed · Cited by 1
Thamnostylum piriforme, a novel etiological agent of superficial mycosis
Sharma, B., & Nonzom, S. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.106544 · Cited by 1
Pharmacokinetics of voriconazole in horses and alpacas
Chan, H. M. (2008) · Cited by 1
Advances in antimicrobial therapy
Pavia, A. T. (1999) · Seminars in Pediatric Neurology · doi:10.1016/s1071-9091(99)80027-8 · Cited by 1
Actualités thérapeutiques des mycoses rares en dehors des mycoses opportunistes
Maslin, J., & Develoux, M. (2004) · EMC-Maladies infectieuses/Encyclopédie médico-chirurgicale. Maladies infectieuses · doi:10.1016/j.emcmi.2004.07.001 · Cited by 1
Moore, C. B., & Denning, D. W. (2010) · doi:10.1002/9780470688618.taw0163 · Cited by 1
Antifungal Treatment (Topical/Systemic)
Giger, R., Landis, B. N., Stow, N. W., & Lacroix, J. (2010) · Springer eBooks · doi:10.1007/978-3-642-11412-0_24
Onicomicosis por Chrysosporium
Huguet, J. L. B., & Gaviño, P. N. (2012) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(12)70306-7
Fallbericht. ZNS-Infektion durch Penicillium chrysogenum
Lu, A., de Hoog, S., Samson, R. A., & Vural, M. (2004)
Fokkens, W. J., & Pundir, V. (2015) · Springer eBooks · doi:10.1007/978-3-319-16724-4_17
Clinically Promising New Triazoles for Systemic Fungal Infections
Neely, M. N., Sheehan, D. J., & Ghannoum, M. A. (2004) · Springer eBooks · doi:10.1007/978-3-662-10380-7_16
Antimikrobielle Therapie bei ausgewählten Infektionen
Halle, E., Göbel, U. B., Kastrup, M., Spies, C., & Nolte, N. (2003) · Springer eBooks · doi:10.1007/978-3-662-06233-3_24
A Case of Mandibular Osteomyelitis Caused by Geotrichum candidum
başkol, D., Akyol, D., Tasbakan, M. I., Metin, D. Y., Yamazhan, T., Sıpahı, O. R., & Pullukçu, H. (2019) · ANKEM Dergisi · doi:10.5222/ankem.2019.1912
Subcutaneous Foot Phaeohyphomycosis due to Alternaria alternata
Jakkan, M. S., Agashe, V. M., & Almeda, A. (2015) · Journal of Foot and Ankle Surgery (Asia Pacific) · doi:10.5005/jp-journals-10040-1028
Seebacher, C. (2001) · Springer eBooks · doi:10.1007/978-3-642-56567-0_8
Perfect, J. R. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-21
Tiña por Nannizzia nana: caso clínico y revisión bibliográfica
Ulerio, J. P., Martins-Lopes, M., Garcı́a-Garrote, F., Hernández-Calvo, P., Yuste‐Chaves, M., & Zufiaurre, M. N. G. (2022) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2022.05.011
Ringworm by Nannizzia nana: Clinical case and literature review
Ulerio, J. P., Martins-Lopes, M., Garcı́a-Garrote, F., Hernández-Calvo, P., Yuste‐Chaves, M., & Zufiaurre, M. N. G. (2023) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2023.03.001
Metadata
- Authors
- Wildfeuer, A., Seidl, H. P., Paule, I., & Haberreiter, A.
- Affiliations
- Pfizer (United States) (US)
- Technical University of Munich (DE)
- Corresponding author
- Wildfeuer, A.
- Venue
- Mycoses
- Publisher
- Wiley
- Published
- 1998-09
- Volume
- 41
- Issue
- 7-8
- Pages
- 309-319
- ISSN
- 0027-5557 (ISSN-L)
- 0933-7407
- 1439-0507
- OpenAlex
- W1992535097
- Cited by
- 140
- References
- 20
- Citations by year
- 2024: 5 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 2 · 2015: 7 · 2014: 5 · 2013: 3 · 2012: 2
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Mycoses (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- voriconazole, antifungal activity, yeast, molds, dermatophytes, itraconazole, ketoconazole, amphotericin B, griseofulvin, minimum inhibitory concentration, Aspergillus fumigatus, Zygomycetes, triazole antifungals, clinical isolates
- MeSH terms
- Amphotericin B, Antifungal Agents, Fungi, Griseofulvin, Humans, Ketoconazole, Microbial Sensitivity Tests, Mycoses, Pyrimidines, Triazoles, Itraconazole, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
